Status:
COMPLETED
The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Fetal Heart Failure (Disorder)
Eligibility:
FEMALE
18-44 years
Brief Summary
Pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean section will be recruited for the study. Data regarding maternal resting heart rate and fetal baseline hea...
Detailed Description
Pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean section will be recruited for the study. After signing an informed consent, data regarding maternal restin...
Eligibility Criteria
Inclusion
- Pregnant women between 32 and 41 weeks' gestation undergoing either vaginal or cesarean delivery with a fetal baseline heart rate of 110-130 beats per minute and 140-160 beats per minute.
Exclusion
- Delivery before 32 weeks of gestation
- Maternal bradycardic (\<60) or tachycardic (\>100) resting heart rate.
- Fetal bradycardia (\<110) or tachycardia (\>160).
- Suspected chorioamnionitis
- Maternal diseases which can affect her heart rate such as:
- Cardiac disease (including arrhythmias)
- Diseases of the thyroid gland
- Rheumatic diseases
- Use of medication which alters heart rate such as:
- Beta blockers
- Beta agonists
- Cocaine, amphetamines
- Use of Pethidine and Phenergan during delivery
Key Trial Info
Start Date :
February 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT03478267
Start Date
February 17 2019
End Date
March 1 2021
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam hospital
Haifa, Israel